Thu, Apr 17, 2014, 9:55 AM EDT - U.S. Markets close in 6 hrs 5 mins

Recent

% | $
Quotes you view appear here for quick access.

United Therapeutics Corporation Message Board

  • lws2000 lws2000 Jun 9, 2005 12:01 PM Flag

    PAH & ED-- what a combination

    How does this effect UTHR? Is this a something that will enhance the effectiveness of Remodlin or replace it? PLEASE COMMENT.
    ------------------------------------------

    FDA Clears Pfizer Hypertension Drug

    Pfizer (PFE:NYSE - commentary - research) said Monday that the Food and Drug Administration has approved a new treatment for a rare blood-vessel disease, endorsing a drug that has the same main ingredient found in the impotence product Viagra.

    The agency's support of the drug Revatio marks the second pill approved for the rare condition known as pulmonary arterial hypertension, or PAH. The disease is characterized by dangerously high blood pressure in blood vessels leading from the heart to the lungs. Without treatment, patients could die within three years of diagnosis, Pfizer says. Symptoms include fatigue, dizziness and difficulty breathing.


    Revatio should reach the market in mid-July. "Revatio demonstrates our commitment to developing treatments for unmet medical needs, including rare conditions such as PAH, regardless of commercial potential," said Dr. Joe Feczko, Pfizer's chief medical officer. Pfizer's shares rose 3 cents to $27.99.

    The company spent six years testing Revatio for PAH. The transforming of a compound for erectile dysfunction into a treatment for PAH isn't such a stretch, because both Viagra and Revatio work by improving blood flow by relaxing blood vessels. After all, when Pfizer started studying the drug that eventually became Viagra, the goal was to find a new blood-pressure treatment.

    Although Pfizer says PAH affects about 100,000 people worldwide, the market is crowded with treatments and experimental products. The other PAH pill on the market is Tracleer from the Swiss company Actelion.

    In addition, United Therapeutics (UTHR:Nasdaq - commentary - research) and GlaxoSmithKline (GSK:NYSE - commentary - research) make PAH drugs injected under the skin or administered intravenously. And CoTherix (CTRX:Nasdaq - commentary - research) received FDA approval in late December to market an inhalable PAH drug called Ventavis. The drug is licensed from the German drug company Schering AG (SHR:NYSE

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Review
      WASHINGTON, June 7-The FDA has approved Revatio, a new formulation of Viagra (sildenafil), for treatment of pulmonary arterial hypertension (PAH).

      "That study enrolled 277 patients with PAH, 38% of whom were New York Heart Association (NYHA) functional class II and 58% were NYHA class III."

      As far as I can see Revatio is only licenced for Class 11 & 111. As I have said before, all roads still lead to Class 1V and to Remodulin.

      And one of things that has often been said of Remodulin is that IT DOES NO HARM. This was even a comment of the FDA when they granted the licence. Let's see how Revatio gets on over time. Remember Tracleer was going to be the wonder drug, then it was discovered that 25% of those taking it showed signs of liver toxicity and had to come of it!

      Also not much is written on these boards about the benefits of inhaled treatments. When UTHR is granted a licence for inhaled Remodulin, because of its much longer half life it will be the drug of choice and the Schering AG product will be squeezed out. I think you will find this is going to be a widely used therapy.

      I also think you will find, over time, just about every drug mentioned as being the finish of Remodulin will be used WITH Remodulin in a combination therapy.

      The people who mark this stock down do not understand the disease area. There is no magic bullit. Yes, I am sorry I didn't have the foresight to get out this time at $57 and back in at $47 (I had done a few times when it was in the $10's & $20's a couple of years ago) but I believe this is stock for the longhaul.

      • 2 Replies to pinotnoirfan
      • >> I also think you will find, over time, just about every drug mentioned as being the finish of Remodulin will be used WITH Remodulin in a combination therapy<<

        Of course this is the hope, and I also believe this. I don't know enough about the differences between Remodulin and Revatio (really Viagra) to know if Remodulin does anything better than Revatio.

        The best of all worlds would be if the combo is superior to the effect of either drug alone. Does anyone have any ideas about this?

      • Nice post. As you have reminded us, the announced death of Remodulin is premature. What will physicians prescribe? A newbie that has no track record or something established that works? What would you take?

        Then there's other developments within the company besides the x-Rexs. Don't they get any respect?

    • From the article that you quote, it appears that PFE now has 'locks' on the PAH market. The same problem effects both parts (lungs and the kingly-organ)---lack of circulation in critical parts. Blue Viagra and its white twin sister (Revatio) seem detined to dominate certain treatmenst for rare blood-vessel diseases.

      Remodulin is dead as a door-nail.Revatio is extremely safe, and effective.

 
UTHR
98.27+0.05(+0.05%)9:55 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.